overdose of semaglutide and Opioid Risk in Patients With Type 2 Diabetes and Opioid Use Disorder GLP-1 medications like semaglutide and

Intestinal Anti-Inflammatory Activity (KPV): KPV (Lys-Pro-Val) is a tripeptide that research suggests can attenuate NF-kB signaling in intestinal epithelial cells, reducing pro-inflammatory cytokine expression relevant to colitis models

The effects of DSIP appear to persist beyond the single night of administration for some individuals, potentially allowing less frequent dosing while maintaining benefits

Imaging or DEXA for body composition may be included if visceral fat is a primary clinical concern

Left panel shows the effects of MYTHO inhibition in mammalian cells

Note that glucagon is not itself an incretin hormone